Which statement best describes 21 CFR Part 58?

Which statement best describes 21 CFR Part 58?

• A. Good laboratory practice for nonclinical laboratory studies
• B. Good manufacturing practice for devices
• C. Clinical trial endpoints
• D. Post-market surveillance requirements

Answer: (A)

The statement tested here focuses on Good Laboratory Practice for Nonclinical Laboratory Studies. 21 CFR Part 58 sets the standards for how nonclinical safety studies are planned, conducted, recorded, reported, and stored to ensure the data’s quality and integrity that regulatory submissions rely on. It governs the responsibilities of the sponsor, the facilities conducting the studies, and the quality assurance unit, and it requires proper documentation and archiving so the work can be reviewed and replicated if needed. This regulation applies to nonclinical work, such as animal or in vitro safety studies, not to manufacturing processes, clinical trial endpoints, or post-market surveillance.

The statement tested here focuses on Good Laboratory Practice for Nonclinical Laboratory Studies. 21 CFR Part 58 sets the standards for how nonclinical safety studies are planned, conducted, recorded, reported, and stored to ensure the data’s quality and integrity that regulatory submissions rely on. It governs the responsibilities of the sponsor, the facilities conducting the studies, and the quality assurance unit, and it requires proper documentation and archiving so the work can be reviewed and replicated if needed. This regulation applies to nonclinical work, such as animal or in vitro safety studies, not to manufacturing processes, clinical trial endpoints, or post-market surveillance.